Merck Deal's 300 Percent Premium Fell Short of Most Bullish Hope

(Bloomberg) -- Even at a 300 percent premium, Merck & Co.’s deal to buy Immune Design Corp. still managed to miss at least two sell-side analysts’ most bullish outlooks for the small-cap drugmaker.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.